Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis

Hebeisen, Monika; Scherer, Almut; Micheroli, Raphael; Nissen, Michaël; Tamborrini, Giorgio; Möller, Burkhard; Zufferey, Pascal; Exer, Pascale; Ciurea, Adrian

doi:10.1371/journal.pone.0216746

Scientific article

English

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis

ContributorsHebeisen, Monika; Scherer, Almut; Micheroli, Raphael; Nissen, Michaël; Tamborrini, Giorgio; Möller, Burkhard; Zufferey, Pascal; Exer, Pascale; Ciurea, Adrian

Published inPLOS ONE, vol. 14, no. 5, e0216746

Publication date2019

Abstract

To compare drug survival in patients with axial spondyloarthritis treated with different TNF inhibitors in standard dosage.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Recherche clinique dans les rhumatismes inflammatoires (1010)

Citation (ISO format)

HEBEISEN, Monika et al. Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. In: PLOS ONE, 2019, vol. 14, n° 5, p. e0216746. doi: 10.1371/journal.pone.0216746

Article (Published version)

CC BY

Identifiers

PID : unige:134045
DOI : 10.1371/journal.pone.0216746
PMID : 31145730

Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542531/

Journal ISSN1932-6203

310views

195downloads

Creation05/12/2019 10:59:00

First validation05/12/2019 10:59:00

Update03/02/2025 12:56:53

Status update03/02/2025 12:56:53

Last indexation03/02/2025 13:01:53

Archive ouverte UNIGE

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis

To compare drug survival in patients with axial spondyloarthritis treated with different TNF inhibitors in standard dosage.

Technical informations